Abivax (ABVX) Capital Expenditures (2024 - 2026)

Abivax's Capital Expenditures history runs 3 years deep, the most recent figure standing at -$63220.3 for Q1 2026.

• In Q1 2026, Capital Expenditures fell 36.6% year-over-year to -$63220.3; the TTM figure through Mar 2026 stood at $153941.5 (down 75.92% YoY), while the FY2025 annual figure was $165294.2, down 75.83% from the prior year.
• Capital Expenditures was -$63220.3 for Q1 2026 at Abivax, down from $229316.6 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.3 million in Q4 2024 to a low of -$341546.3 in Q3 2024.
• Historically, Capital Expenditures has averaged $86697.3 across 3 years, with a median of -$21507.2 in 2025.
• Biggest YoY gain for Capital Expenditures was 102.74% in 2025; the steepest drop was 255.03% in 2025.
• A 3-year view of Capital Expenditures shows it stood at $1.3 million in 2024, then plunged by 81.92% to $229316.6 in 2025, then sank by 127.57% to -$63220.3 in 2026.
• The last three Capital Expenditures figures came in at -$63220.3 (Q1 2026), $229316.6 (Q4 2025), and $9352.4 (Q3 2025), per Business Quant data.